



**Product Parameters** >>

<b>Testing Speed</b>	120-4000 T/H (According to the targets per assay/joint assay, testing speed is calculated by 120 samples x joint assay number)	<b>Reagent Area</b>	25 Reagent Slots
	First Report Time: 38 mins		Comes with Refrigeration Function (4-10°C) Supports BarCode Reading
<b>Testing Principle</b>	Multiplexed Bead Flow Fluorescence Technology	<b>Consumables Area</b>	Single-use Pipette Tips to Prevent Cross-contamination
<b>Processing Method</b>	Automatic Processing Method Supports A&E Testing with Cut-the-queue Priority Slots		600 Pipette Tips Slots 600 Reaction Cup Slots
<b>Reaction Area</b>	76 Reaction Cup Slots	<b>Calibration Method</b>	Calibration Type: Batch Calibration
	Temperature Accuracy: <0.5°C		Calibration Mode: 2 or 6 Spot Calibration
	Temperature Fluctuation: <1°C	<b>Size</b>	1030 mm (W) x 1320 mm (L) x 1260mm (H) Weight: 400KG
<b>Sample Area</b>	125 Regular Sample Slots, 15 A&E Testing Slots Both Supporting Different Types of Blood Containers	<b>Software System</b>	Machine Operation and Analysis in One Software
	Supports BarCode Reading		Everyday Maintenance such as Start-up, Washing, and Shut-down
	Supports Automatic Dilution		Supports Automatic Calibration and Quality Control Automated Calculation of All Analyzed Assays
		<b>Others</b>	Supports LIS/HIS Connection
			Supports Formation of Assembly Line

Tellgen Corporation, founded in 2003, is an in vitro diagnostics company located in the the 'global research centre' Zhangjiang Hi-Technology Park in Shanghai, P.R. China. We are a listed company focusing on research and producing high-end IVD products.

With our company's slogan "Deeper Understanding of Life", we aim to explore the scientific field of research and bring our research results to help aid in auxillary diagnosis. We focus on early-stage tumor screening to provide diagnostic help, determination of personalized medicine, and the prediction of drug use.

Tellgen Corporation is the first to release the TESMI system, based on the high-throughput flow fluorescence mutiplexed bead technology, leading a role in the IVD industry. Until now, we have different detection platforms covering immunology, molecular biology, boichemistry, mass spectrometry and more that uses technologies such as multiplexed bead flow fluorescence, chemiluminescence, multiplex-PCR, liquid chromatography tandem mass spectrometry and others. Our products range from full-course tumor monitoring, reproductive health detection, autoimmunity detection, infectious diseases detection, cardiovascular disease detection, and DNA methylation detection. We have innovative products such as tumor marker joint assay (first in China to release), the first CFDA-approved Y chromosomal microdeletion detection kit, and the first CFDA-approved SHOX2+RASSF1A DNA methylation detection kit for lung cancer screening.

We have a stable cooperation with Hitachi and collaborated to release the Hitachi-Tellgen compatible assembly line which offers high-throughput sample pre-treatment and biochemical analyzing system. With the addition of TESMI F4000 to this assembly line, we can achieve high-throughput target detection.

Tellgen insists to adhere to research and actively collaborates with companies from around the world to produce new innovative products and contribute to human health.



**Automated Multiplexed Bead Flow Fluorescence Immunoanalyzer**

**TESMI F4000**

**Tellgen Corporation**

Address: Building 1, No. 115, Lane 572, Bibo Road, Free Trade Area, Shanghai, People's Republic of China  
 Postal Code: 201203  
 Website: www.tellgen.com  
 Email: sales@tellgen.com  
 Tel: +86-21-50800020



Official Website



WeChat Programme



## Tellgen's Automated Multiplexed Bead Flow Fluorescence Immunoanalyzer

Tellgen's Automated Multiplexed Bead Flow Fluorescence Immunoanalyzer is developed and designed by Tellgen Corporation based on flow fluorescence multiplexed bead technology. This detection system gathers advantages of both flow fluorescence and multiplexed bead array assay, realizing high-throughput detection with multiple markers with high sensitivity and excellent repeatability. Tellgen perfectly combines flow fluorescence technology and immune sample pre-treatment, enabling this detection platform to have better temperature control and easier maintenance.



### Technological Advantages >>

#### ✓ High-throughput with joint detection assays, reaching up to 4000 T/H

This system is able to detect 120 samples per hour with up to 35 targets per sample. This realizes a total of 120-4000 targets per hour with 120 samples, making this system more than 10 times more efficient than traditional chemiluminescence analyzers.

#### ✓ Multiple reagent slots for detection of up to a hundred targets in one run on a single machine

There are 25 reagent slots with 4 targets per channel, making this machine able to detect 100 targets in a single machine. Detection target number depends on the corresponding kit. This greatly reduces the number of machines needed and eliminates the need to separate samples onto different machines.

#### ✓ Integrated design for better temperature control and maintenance

The detection module and sample pre-treatment modules are integrated in this machine, making temperature control and daily maintenance easier.

#### ✓ Fully automated and can attached to assembly lines

Supports two-way communication, continuous sampling, emergency testing, and integration into the Hitachi-Tellgen assembly line.

### Applicable Fields >>

- ✓ 21 Tumor Marker Assays**
- ✓ 4 Liver Fibrosis Marker Assays**
- ✓ FlowAI Series for Autoimmunity Assays**
- ✓ 10 ToRCH Assays**
- ✓ Quantitative fecal occult blood test (FOBT)**

### Compatible Assays >>

#### ✓ 21 Tumor Marker Assays

- AFP
- CEA
- CA242
- CA125
- NSE
- CYFRA21-1
- HE4
- t-PSA
- ProGRP
- CA19-9
- CA15-3
- CA72-4
- G17
- SCCA
- CA50
- AMH

#### Special Joint Detection Assays

##### • 2 frequently used tumor markers

CEA  
AFP

\* Mainly targets hepatic carcinoma and other digestive system tumors

##### • 2 prostate cancer markers

t-PSA  
f-PSA

\* Preferred markers for male prostate cancer

##### • 2 gastric cancer markers

PGI  
PGII

\* Helps identify high-risk gastric cancer groups by using serological biopsy of gastric mucosa

##### • 3 lung cancer tumor markers

CEA  
CYFRA21-1  
NSE

\* Can be used on top of CA125 and SCCA Assays for a more thorough screening

##### • 7 selected tumor markers

AFP            CA125  
CEA            CA242  
NSE            free-β-HCG  
CYFRA21-1

\* Covers more than 85% of commonly seen malignant tumors

##### • Other combinations

\* On top of these joint assays, we can add any other assays to these joint combinations according to specific needs

#### ✓ 10 ToRCH Assays

##### ToRCH IgM

- Toxo IgM
- Rubella IgM
- CMV IgM
- HSV-I IgM
- HSV-II IgM

##### ToRCH IgG

- Toxo IgG
- Rubella IgG
- CMV IgG
- HSV-I IgG
- HSV-II IgG

#### ✓ Autoimmunity Assays (FlowAI Series)

- 16 Assays for Antinuclear Antibody
- Assay Type I Diabetes
- 3 Assays for Vasculitis Antibody
- 4 Assays for Antiphospholipid Antibody
- Autoimmune Liver Disease Antibody
- Assay for Myositis Antibody
- Assay for Anti-CCP Antibody
- Assay for Neuroimmunity Antibody

#### ✓ Other Assays

Quantitative fecal occult blood test (FOBT), liver fibrosis assays, etc.